Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cellegy Pharmaceuticals, Inc.
European regulatory authorities revoke patent related to Cellegesic
January 14th, 2004
Cellegy Pharmaceuticals, Inc., (CLGY) announced that the Board of Opposition of the European Patent Office has rendered a verbal decision revoking Cellegy's European patent relating to its Cellegesic (nitroglycerin ointment) product and related compounds for the treatment of anal disorders, including fissures and various hemorrhoidal conditions. Oppositions to the issued patent had previously been filed with the European Patent Office, and the verbal decision followed an oral proceeding before the Board. The Opposition Board will issue a written decision at a future date. Cellegy disagrees with the verbal decision and is evaluating issues available...
Source: Biotech Week (2004-01-14)
|
